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ORIGINAL ARTICLEMultidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of
pyrazinamide plus levoﬂoxacin prophylaxis and serial interferon gamma
release assaysA. Bedini1, E. Garlassi6, C. Stentarelli2, S. Petrella2, M. Meacci3, B. Meccugni3, M. Meschiari1, E. Franceschini1, S. Cerri4,
A. Brasacchio1, F. Rumpianesi3, L. Richeldi7 and C. Mussini5
1) Clinic of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, 2) Medical Department, Sant’Anna Penitentiary, 3) Service of
Microbiology, Azienda Ospedaliero-Universitaria, Policlinico of Modena, 4) Clinic of Lung Diseases, University of Modena, 5) Clinic of Infectious Diseases, University
of Modena and Reggio Emilia, Modena, 6) Department of Infectious Diseases, Ospedale Santa Maria Nuova, Reggio Emilia, Italy and 7) University of
Southampton, Southampton, UKAbstractThe optimal treatment for latent tuberculosis infection (LTBI) in subjects exposed to multidrug-resistant (MDR) tuberculosis (TB) remains
unclear, and the change in response of the QuantiFERON-TB Gold In-Tube (QTB-IT) test during and after treatment is unknown. Between
May 2010 and August 2010, 39 prisoners at the ‘Casa Circondariale’ of Modena, Italy, were exposed to a patient with active pulmonary MDR
TB. All contacts were tested with the tuberculin skin test and QTB-IT. Upon exclusion of active TB, subjects positive to both tests were
offered 6 months’ treatment with pyrazinamide (PZA) and levoﬂoxacin (LVX). QTB-IT testing was repeated at 3 and 6 months after
initial testing in all subjects who were offered LTBI treatment. Seventeen (43.5%) of 39 subjects tested positive to both tuberculin skin
test and QTB-IT test, and 12 (70.5%) agreed to receive therapy with PZA and LVX at standard doses. Only ﬁve (41.6%) of 12 subjects
completed 6 months’ treatment. Reasons for discontinuation were asymptomatic hepatitis, gastritis and diarrhoea. The QTB-IT values
decreased in all subjects who completed the treatment, in two (33%) of six of those who received treatment for less than 3 months and
in one (50%) of two patients who discontinued therapy after 3 months. The QTB-IT test results never turned negative. Despite the small
number of subjects, the study conﬁrmed that PZA plus LVX is a poorly tolerated option for MDR LTBI treatment. We observed a large
degree of variation in the results of the QTB-IT test results among participants. The study conﬁrmed that the interferon gamma release
assay is not a reliable tool for monitoring the treatment of MDR LTBI in clinical practice.
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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E-mail: andreabedini@yahoo.comIntroductionMultidrug-resistant (MDR) tuberculosis (TB) is deﬁned as Myco-
bacterium tuberculosis that is resistant at least to isoniazid (INI) and© 2016 The Authors. Published by El
This is an orifampicin (RIF). Extensively drug-resistant (XDR) TB is deﬁned as
M. tuberculosis resistant to INI, RIF, any ﬂuoroquinolone and at
least one of three injectable second-line drugs (capreomycin,
kanamycin and amikacin) [1]. As the number of people with MDR
TB or XDR TB increases, so does the number of their contacts,
and it is precisely these contacts who need to be identiﬁed and
properlymanaged. Themanagement of contacts ofMDRandXDR
TB patients is particularly challenging, as the evidence for the best
intervention is limited. In drug-susceptible TB, preventive therapy
in individuals with latent TB infection (LTBI) has been shown to beNew Microbe and New Infect 2016; 12: 45–51
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The concept is also valid forMDRandXDRTBbut is limited by the
current lack of availability of effective drugs against MDR andXDR
TB infections, with an unacceptable adverse event (AE) proﬁles in
otherwise healthy individuals. During the past decades, the
treatment recommended for LTBI in contacts exposed to MDR
TB was pyrazinamide (PZA) combined with either ethambutol
(ETB) or a ﬂuoroquinolone [3]. These recommendations were
supported by expert opinion but not by controlled trials [4]. Some
reports have highlighted the potential hepatotoxicity of combined
treatments of PZA plus ETB and PZA plus levoﬂoxacin (LVX) for
MDR LTBI [5,6], inducing theWorld Health Organization and the
international community to change the approach to the contacts
of MDR TB cases, preferring a careful clinical follow-up of 2 years
rather than antibiotic treatment [7].
Interferon gamma (IFN-γ) release assays (IGRAs) are impor-
tant tools for LTBI diagnosis and surveillance for new TB infection
[8–10]. IGRAs are in vitro assays based on the detection of IFN-γ
production in response to early-secreted antigenic target 6 kDa
protein (ESAT-6) and culture ﬁltrate protein 10 (CFP-10). These
antigens are speciﬁc to M. tuberculosis and are absent from all ba-
cillus Calmette-Guérin vaccine strains and most environmental
mycobacteria [11,12]. The QuantiFERON-TB Gold In-Tube
(QTB-IT; Cellestis, Valencia, CA, USA) test contains a third
M. tuberculosis–speciﬁc antigen (TB7.7) anduses an enzyme-linked
immunosorbent assay for detection of IFN-γ responses. The US
Centers for Disease Control and Prevention have recommended
the use of the QTB-IT test as an appropriate substitute for the
tuberculin skin test (TST) in contact investigations [13]. Inter-
pretation of serial IGRAs is challenging because of nonspeciﬁc
variation, conversions and reversions. Previous studies have
proposed that conversions, reversions and nonspeciﬁc variations
occur with both serial IGRAs and TST [14–19]. In addition, pre-
vious TST results may boost the subsequent IGRA responses,
rendering the interpretation of serial IGRA results more difﬁcult
[20]. Until now, in LTBI subjects, most serial IGRAs were per-
formed after INI or rifampin preventive treatment [21–23].
However, to our knowledge, there are no reports evaluating serial
IGRAs after treatment for MDR LTBI with PZA plus LVX.
The aim of the present study was to evaluate the tolerance
of the MDR LTBI treatment and the kinetics of QTB-IT in three
groups of patients: those who concluded 6 months’ treatment
with PZA and LVX, those who received less than 6 months’
treatment and those who refused treatment.Patients and MethodsOne inmate of ‘CasaCircondariale S. Anna’ penitentiary (Modena,
Northern Italy)wasdiagnosedwith active pulmonaryTB inAugust© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
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pulmonary TB, and susceptibility testing of the M. tuberculosis
strain showed resistance to RIF and INI as well as reduced sus-
ceptibility to ETB (resistance to 5.00 μg/mL, susceptibility to
7.50 μg/mL). The investigation of the outbreak was initiated by
performing TST and QTB-IT tests in all individuals who had con-
tact with the index case during the 2 months before the diagnosis.
To exclude other cases of active TB, all the individuals who had
positive results for both the TST and QTB-IT test underwent
chestX-ray and a high-resolution computed tomographic (HRCT)
scan of the chest. All patients who tested positive by TST and
QTB-IT with a normal chest HRCT result were considered for 6
months’ directly observed LTBI treatment regimen including PZA
and LVX. Acceptance of LTBI treatment required written
informed consent. Theprophylactic regimenwas administrated by
directly observed therapy. HIV, hepatitis C virus and hepatitis B
virus serology were performed before treatment; liver function
testing (aspartate aminotransferase (AST) and alanine amino-
transferase (ALT)) was performed at baseline, 2 weeks after the
beginning of treatment and then monthly. LTBI treatment was
discontinued if the increase in ALT or AST was greater than four
times the upper limit of normal (ALT, 42 IU/L; AST, 42 IU/L) or if
the patient experienced drug-related AEs.
The QTB-IT test was repeated after 3 and 6 months in all
subjects.
Tuberculin skin test
TST was administered using the Mantoux method with 2TU
PPD RT23 (Statens Serum Institute, Copenhagen, Denmark)
[3]. The induration size was measured after 48 to 72 hours by a
trained medical doctor, and a 10 mm induration size was set as
the cutoff value.
QTB-IT test
All participants were tested by QTB-IT as per the manufacturer’s
instructions (http://www.quantiferon.com/irm/content/
quantiferon-tb-gold1.aspx?RID=300). An IFN-γ response to the
ESAT-6/CFP-10/TB7.7 mixture 0.35 IU/mL above the nil con-
trol value (and25% of the nil control) was considered a positive
result for theQTB-IT test. If a response toM. tuberculosis–speciﬁc
antigens (corrected for the nil control) was <0.35 IU/mL and the
response to the positive control was >0.5 IU/mL, then the
response was considered negative. Indeterminate results were
classiﬁed as nil-corrected IFN-γ responses <0.35 IU/mL and
positive control responses<0.5 IU/mL.QTB-IT test reversionwas
arbitrarily deﬁned as a change from a positive (0.35 IU/mL) to a
negative (<0.35 IU/mL) result.
When the QTB-IT antigen-speciﬁc value was >10.0 IU/mL,
we performed a 1:10 dilution of the plasma samples and we
repeated the IGRA determination; ﬁnally, the QTB-IT value was
multiplied by 10.iology and Infectious Diseases, NMNI, 12, 45–51
.0/).
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A total of 39 subjects were screened with TST and QTB-IT
test, which were positive in 58.9% and 43.5%, respectively.
The 17 individuals with positive TST and positive QTB-IT test
underwent chest x-ray and HRCT scan. Results of the radio-
logic examinations were all negative, and the 17 patients were
included in the study (Fig. 1, Table 1). The subjects were all men
with a mean age of 34 years (range, 21–51 years); 13 (76.5%)
were foreign born and came from countries highly endemic for
TB (Table 2). The LTBI treatment with PZA (20–25 mg/kg/day)
and LVX (500 mg/day) was offered to all 17 individuals but was
accepted by only 12 (70.5%) of them. The patients who
received LTBI treatment had a mean weight of 70 kg (range,
59–95 kg), and all were negative for HIV, hepatitis C virus and
hepatitis B virus infection. All the patients were smokers, and
four (33.3%) of 12 subjects were regularly takingFIG. 1. Flow diagram of contact
investigation of infectious tubercu-
losis patients (n = 39). Ag IFN-γ,
antigen-speciﬁc IFN-γ; LVX, levo-
ﬂoxacin; PZA, pyrazinamide; QTB-
IT, QuantiFERON-TB Gold In-Tube;
TST, tuberculin skin test.
© 2016 The Authors. Published by Elsevier Ltd on behal
This is an obenzodiazepines or neuroleptic drugs. The median duration of
LTBI treatment was 108 days (range, 27–180 days); only ﬁve
patients (41.6%) completed the 6-month course of therapy. The
main AE observed during the LTBI treatment was asymptom-
atic hepatitis (n = 6, 50.0%), followed by diarrhoea (n = 2,
16.6%), gastritis (n = 2, 16.6%), headache (n = 1, 8.3%) and
arthritis (n = 1, 8.3%). In one patient (8.3%), an asymptomatic
increase of plasma uric acid concentration occurred. The
number of subjects reporting AEs and the number of therapy
discontinuations due to AEs are reported in Table 3.
Serial QTB-IT test
The QTB-IT test was repeated after 3 and 6 months in all
subjects who were initially offered LTBI treatment (n = 17). The
kinetics of QTB-IT tests is shown in Fig. 2 and Table 2. The
QTB-IT test never converted to negative, but antigen-speciﬁc
IFN-γ (Ag IFN-γ) levels decreased in all subjects who
completed the treatment and in all patients who received <6
months’ LTBI treatment. No relationship between baseline TSTf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 12, 45–51
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
TABLE 1. Clinical characteristics of 17 subjects with positive
TST and QTB-IT test for multidrug-resistant LTBI
Characteristic Value
Male sex 17 (100%)
Age, years, mean (range) 34 (21–59)
Italian origin 4 (23.5%)
History of active TB 0
HIV, HBV, HCV infection 0
Weight, kg, mean (range) 71 (59–95)
TST induration, mm, mean (range) 20 (10–32)
Baseline QTB-IT, IU, mean (range) 18.00 (1.98–89.40)
Acceptance of LTBI treatment 12/17 (70.5%)
Conclusion of LTBI treatment 5/12 (41.6%)
Duration of LTBI treatment, days, median (range) 108 (27–180)
HBV, hepatitis B virus; HCV, hepatitis C virus; LTBI, latent tuberculosis infection;
QTB-IT, QuantiFERON-TB Gold In-Tube; TST, tuberculin skin test.
TABLE 3. AEs reported by contacts during multidrug-
resistant latent tuberculosis infection treatment
AE
Patients with AEs treated
with PZA/LVX, n (%)
Therapy discontinuation
for AE, n (%)
Hepatitis 6 (50.0) 5 (41.6)
Diarrhoea 2 (16.6) 1 (8.3)
Gastritis 2 (16.6) 1 (8.3)
Dizziness/headache 1 (8.3) 0 (0.0)
Arthritis 1 (8.3) 0 (0.0)
None 3 (25.0) 0 (0.0)
AE, adverse event; LVX, levoﬂoxacin; PZA, pyrazinamide.
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was observed. The kinetics of the Ag IFN-γ levels in the ﬁve
patients who refused prophylaxis showed discordant results: in
three patients (60.0%) we observed an increase of the QTB-IT
value, and in two (40.0%) we observed a decrease (Fig. 1).
During 24 months’ follow-up, none of the patients developed
active pulmonary or extrapulmonary TB.DiscussionAlthough the incidence of MDR TB is low, one of the most
important strategies to contain its spread would be the pre-
vention of active MDR TB through effective LTBI treatment.
Preventive therapy of patients with drug-susceptible LTBI has
been proven to be effective and is included in guidelines for TB
control [22]. Unfortunately, no treatment regimens for MDR
LTBI have been tested in a randomized, controlled trial [24].
Therefore, the question remains of how to treat MDR LTBI, or
even whether to treat it. Attamna et al. [25] described theTABLE 2. Characteristics of 17 subjects exposed to multidrug-resis
Patient No. Age (years) Nationality Duration of LTBI treatment (da
1 34 Nigerian 180
2 36 Italian 179
3 23 Tunisian 180
4 24 Romanian 178
5 32 Romanian 107
6 21 Tunisian 27
7 27 Moroccan 79
8 43 Tunisian 70
9 36 Tunisian 94
10 36 Chinese 180
11 25 Moroccan 70
12 51 Italian 31
13 32 Nigerian 0
14 31 Moroccan 0
15 37 Moroccan 0
16 40 Italian 0
17 48 Italian 0
Ag IFN-γ, antigen-speciﬁc interferon gamma; LTBI, latent tuberculosis infection; ND, not do
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4incidence of MDR TB disease in close contacts (n = 476) of
patients with pulmonary MDR TB (n = 78) after preventive
therapy compared to the incidence in close contacts who did
not receive preventive therapy. The study was performed in
Israel between 1998 and 2006. Follow-up was provided for a
minimum of 3 years, with a maximum of 8 years. In this study,
no cases of TB occurred in either the treated or the untreated
group, so therefore this study provides very limited evidence. In
another study, Schaaf et al. [26] performed a prospective
cohort study in infected (n = 61) and noninfected (n = 44)
children younger than 5 years in household contact with adults
with pulmonary MDR TB (n = 73). The study was conducted in
South Africa between 1994 and 2000. All infected children and
all children younger than 2 years who had received no previous
treatment or preventive therapy of any kind for TB were
offered preventive therapy. This study provides evidence that
preventive therapy—taking into account the resistance proﬁle
of the index case—may prevent TB disease in children (under
the age of 5 years) who are in contact with MDR TB patients.
The risk of developing TB disease was lower in the treated
group, but the risk difference was not signiﬁcant, with a risk
difference of 5% (95% conﬁdence interval, −2 to 11) in favour of
preventive therapy. The study found a signiﬁcant risk differencetant tuberculosis
ys) TST induration size (mm)
Ag IFN-γ (IU/mL)
Baseline 3 months 6 months
11.0 36.20 5.89 6.95
15.0 8.01 1.87 0.97
12.0 9.94 0.68 1.61
25.0 3.96 4.06 1.48
20.0 71.40 26.40 17.40
16.0 37.40 ND 14.30
30.0 87.00 30.50 29.80
25.0 89.40 16.40 27.90
20.0 25.00 4.05 1.71
32.0 1.98 1.82 0.76
25.0 7.84 10.00 3.98
15.0 7.81 4.15 1.98
11.0 55.70 28.00 11.40
20.0 32.10 22.00 16.65
20.0 18.00 9.00 3.29
15.00 2.84 5.5 7.79
16.00 8.85 28.9 43.90
ne; TST, tuberculin skin test.
iology and Infectious Diseases, NMNI, 12, 45–51
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FIG. 2. Kinetics of QTB-IT tests in patients who received 6 months’
LTBI treatment with PZA and LVX (A), patients who interrupted
treatment before 6 months (B) and patients who refused treatment (C).
LTBI, latent tuberculosis infection; LVX, levoﬂoxacin; PZA, pyr-
azinamide; QTB-IT, QuantiFERON-TB Gold In-Tube.
NMNI Bedini et al. TB outbreak in an Italian prison 49of 15% (95% conﬁdence interval, −27 to −4) between treated
and untreated children when assessing conﬁrmed and probable
TB. All three culture-conﬁrmed TB cases occurred in children
not receiving preventive therapy.
In our study, we decided to treat the MDR TB contacts who
were diagnosed with LTBI because they lived in a closed envi-
ronment—a prison—and we considered there to be an
elevated risk of transmission in case there would be a new
episode of active MDR TB. Because the strain of M. tuberculosis
isolated from the index case was resistant to RIF and INI, and
because it showed reduced susceptibility to ETB, we decided to© 2016 The Authors. Published by Elsevier Ltd on behal
This is an otreat LTBI with a combination regimen of LVX and PZA.
Limited data are available on the safety proﬁle of this regimen
when used for LTBI treatment. A systematic review assessed
the AEs in anti-TB preventive therapy (drugs other than INI or
RIF) in healthy individuals [27]. For LVX (six studies, eight study
arms) no severe AEs were reported, and the reason for
dropout was not related to AEs. For PZA, which is always used
in combination with other drugs, four case series on MDR LTBI
treatment are available. Combination therapy was prescribed
for 6 to 12 months (PZA with oﬂoxacin in two studies, with
ETB in one study and with LVX in another study). All these
studies reported a high frequency of AEs. Treatment was dis-
continued in 58% to 100% of the subjects as a result of AEs that
ranged from mild, such as nausea and dizziness, to serious ones
requiring treatment. An increase in liver enzymes was a reason
for treatment discontinuation in 25% to 58% of cases.
In our population, the combination of PZA and LVX was
poorly tolerated, with a rate of treatment interruption of
58.4%. However, comparing our case cohort with that studied
by Papastavros et al. [6] (17 individuals with suspected MDR
LTBI treated with PZA and LVX), we observed a lower inci-
dence of AEs related to the musculoskeletal system (8.3% and
82.3%, respectively), central nervous system (0 and 29.4%,
respectively) and skin (0 and 29.4%, respectively), as well as a
lower rate of increase in plasmatic uric acid (8.3% and 47.0%,
respectively). In addition, the median time of LTBI treatment
was longer in our case cohort (108 and 32 days, respectively).
One possible explanation is that the prisoners may have had a
higher pain threshold than a nonprison population. Another is
that the prisoners had a greater adherence to prophylaxis
because their therapy was directly observed, and the patients
had weekly visits with the infectious diseases specialist during
the treatment period. In our population, only three subjects
(25.0%) did not experience any AEs. In six patients (50.0%) an
increase in AST and ALT was observed, and in ﬁve of them
(41.6%) the increase was fourfold greater than the upper value
of the normal range and required treatment interruption. In all
cases, toxic hepatitis was asymptomatic; it was diagnosed by
monthly screening of liver enzymes.
To our knowledge, this is the ﬁrst study to evaluate the ki-
netics of QTB-IT in patients receiving preventive treatment for
MDR LTBI. Recent research has focussed on the use of IGRAs
as a biomarker indicating treatment success [28,29]. It has been
postulated that a decrease in the magnitude of IFN-γ responses
to M. tuberculosis–speciﬁc peptides measured by IGRA can be
used as a biomarker of cure [30]. In 2013 Denkinger et al. [31]
published a large study on the use of IGRA to monitor anti-TB
treatment response in 149 patients with active TB. A large
proportion of patients remained QTB-IT positive even after
completing treatment. The authors also found substantialf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 12, 45–51
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
50 New Microbes and New Infections, Volume 12 Number C, July 2016 NMNIwithin-subject variability in sequential measurements despite all
patients receiving adequate therapy and having nearly 100%
adherence. They suggested that this within-subject variability
might have been inﬂuenced by exogenous (i.e. incubation time,
contamination with other antigens, different test operators,
other analytical inconsistencies) and endogenous factors (i.e.
antigen burden, cumulative TB exposure, time interval from
exposure, clearance of infection, recent TST, concomitant in-
fections, medications, other unknown factors). In 2015 Clifford
et al. [32] published a large systematic review evaluating serial
IGRA as a potential tool to monitor treatment in patients with
active TB and LTBI (30 studies; 24 used QTB-IT, three used T-
SPOT.TB and three used both QTB-IT and T-SPOT.TB). No
uniform pattern was seen in IGRA conversion or in reversion
rates at the end of treatment for active or latent TB, and in
most studies, the majority of IGRA results remained positive at
the end of treatment. In the larger studies of LTBI, reversion
and conversion rates were 38% and 9%, respectively, using T-
SPOT.TB [21] and 24% and 18% using QTB-IT [33]. The au-
thors concluded that although quantitative IGRA responses
generally fall during treatment for TB, the large degree of
variation in results among participants in each study means that
IGRAs are unlikely to be useful for monitoring anti-TB treat-
ment in clinical practice for any individual patient. In addition,
we observed a large degree of variation in results of QTB-IT
value between participants: the kinetics of QTB-IT showed
decreased Ag IFN-γ levels both in the patients who concluded 6
months’ treatment and in those who did not complete it. We
also noted a decrease in Ag IFN-γ levels in three (60%) of ﬁve
patients who did not receive anti-TB prophylaxis. These data
were probably related to the small number of patients observed
and to a great variation in previous exposure to TB before
arriving at the study center. In conclusion, our study conﬁrmed
that IGRA is not reliable tool for monitoring treatment for
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